Clinical Trial Results: A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating NC410 plus pembrolizumab in advanced/metastatic solid tumors with various MSI statuses; terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Colorectal Cancer
• Endometrial Cancer
• Esophageal Cancer
• Gastric Cancer
• Head and Neck Cancer
• Lung Cancer
• Or Metastatic Solid Tumors
• Ovarian Cancer

Drugs mentioned

• NC410
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: NextCure, Inc. | Conditions: Advanced or Metastatic Solid Tumors, Microsatellite Instability Low | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2026-08-13